sunitinib / Generic mfg. - LARVOL DELTA

Sunitinib attenuates secondary injury via the regulation of peri-hematomal microglia at the acute phase of intracerebral hemorrhage. (PubMed, Neurotherapeutics) - "In BV2 cells, sunitinib inhibited Hb-induced lipid droplet accumulation, phagocytic reduction, and pro-inflammatory cytokine production, effects mirrored by CSF-1R knockdown. These findings suggest that sunitinib alleviates acute ICH injury by modulating microglial functions, likely through inhibition of the CSF-1R axis, supporting its potential repurposing for central nervous system disorders like ICH."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Inflammation • Metabolic Disorders

Atypical hemolytic uremic Syndrome Triggered by malignancy and drug exposure: A systematic review and meta-analysis (ASH 2025) - "Tacrolimus was the mostreported drug trigger (n=6)followed by gemcitabine (n=5), vincristine (n=5), bevacizumab (n=3), carfilzomib (n=3), 6-mercaptopurine(n=2), methotrexate (n=2), and mitomycin (n=2). Aflibercept, bactrim, bleomycin, capecitabine, cisplatin, cyclophosphamide, cytarabine,dasatinib, deferasirox, dinutuximab, estarylla, ketoprofen, L-asparaginase, modakafusp alfa, PEG-asparaginase, sunitinib, syntheticpsychoactive drugs, tamoxifen, and topotecan were reported as potential triggers for aHUS in one patient each...The pooled rate of treatment with eculizumab was 74% (95% CI, 0.629-0.842, p < 0.01, I2 = 72%),and the pooled rate of renal recovery was 65% (95% CI, 0.525-0.761, p < 0.01, I2 = 55%)...AKI and hematological abnormalities in these patients should prompt an emergent work-up and treatment. Current evidenceis primarily derived from case reports, so prospective trials are necessary to establish the incidence, associations, triggers, and outcomes..."

Retrospective data • Review • Acute Kidney Injury • Acute Lymphocytic Leukemia • Anemia • Atypical Hemolytic Uremic Syndrome • B Acute Lymphoblastic Leukemia • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Complement-mediated Rare Disorders • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Hodgkin Lymphoma • Leukemia • Lung Cancer • Lymphoma • Multiple Myeloma • Nephrology • Neuroblastoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor • Thrombocytopenia • Urothelial Cancer

Imatinib and immunosuppression: an overlooked side effect ? (ESMO Asia 2025) - "An enterocutaneous fistula appeared, leading to a three-month Sunitinib course, but no improvement was observed on follow-up scans...Regorafenib was stopped, and Anti-tuberculosis therapy (ATT) was administered... This case report highlights the challenges posed by the coexistence of recurrent GIST and TB infection in a patient. Imatinib, a cornerstone of GIST therapy, not only targets cancer-specific receptors but also modulates T cell function. While not typically considered a predisposing factor for TB, previous reports have suggested potential associations between Imatinib therapies leading to immune-suppression followed by flaring up of tuberculosis."

Adverse events • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Oncology • Sarcoma

Retrospective single-center study comparing the effectiveness of sunitinib and chemotherapy based on alkylating agents in the treatment of metastatic pheochromocytomas/paragangliomas (ESMO Asia 2025) - "Comparative data on the effectiveness of these options are lacking, which is the purpose of this study. This retrospective single-center study included patients (pts) over 18 years of age who received alkylating agents-based ChT (dacarbazine or temozolomide) or sunitinib (SUN) +/- somatostatin analogues (SA) for metastatic PC/PG from September 2015 to January 2025. The study included 46 pts, 23 in each group. Sunitinib and chemotherapy based on alkylating agents demonstrate comparable efficacy in the treatment of metastatic PC/PG. The choice of therapy should be based on the safety profile of the drug."

Metastases • Retrospective data • Endocrine Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor • SDHB

Matrine prevents sunitinib-induced heart failure by restoring MEX3A-mediated autophagy in cardiomyocytes (ESMO Asia 2025) - "Matrine effectively prevents sunitinib-induced heart failure by restoring MEX3A-mediated autophagy in cardiomyocytes. These findings identify MEX3A as a promising biomarker and therapeutic target in precision cardio-oncology and support matrine as a potential protective strategy for cancer patients receiving sunitinib."

Oncology • MEX3A

Prophylactic effect of diclofenac sodium gel on hand-foot syndrome in patients with gastrointestinal cancer treated with tyrosine kinase inhibitors : A single-center prospective observational study (ESMO Asia 2025) - "Secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, tolerability, and QOL (The HFS-14 questionnaire). Between January 2024 and May 2025, 31 patients were enrolled (median age: 67 years [range: 51-80]; male/female: 58%/42%; performance status [PS] 0/1/2: 36%/61%/3%; primary tumor site: colorectal/hepatocellular carcinoma/gastrointestinal stromal tumor: 77%/16%/7%; TKIs: regorafenib/lenvatinib/fruquintinib/sorafenib/sunitinib: 77%/10%/7%/3%/3%. Diclofenac sodium gel application did not reduce the incidence of TKIs-induced grade ≥2 HFS, compared to than the known reports of capecitabine-induced HFS. However, there were no grade≥ 3 HFS and treatment discontinuation due to HFS. Further research on the preventive effects of diclofenac sodium gel for HFS induced by TKIs is warranted."

Clinical • Observational data • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Hepatocellular Cancer • Oncology • Sarcoma • Solid Tumor

Suppressing hyperthermia-induced up-regulated PD-L1 with a Sunitinib loaded Fe-Cu MOF: Strengthening immunogenic cell death to sensitize anti-PD-L1 effect following microwave ablation of hepatocellular carcinoma. (PubMed, Colloids Surf B Biointerfaces) - "Notably, the Fe-Cu MOF@PEG@SUN nanocomposites effectively counteracted MWA-induced PD-L1 upregulation and amplified the extent of ICD post-MWA, thereby enhancing the SUN-mediated anti-PD-L1 immune response and promoting antitumor immunity. Hence, this study offers a promising strategy and theoretical foundation for the integration of diagnostic imaging with MWA-based therapy for HCC."

IO biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • Thermal Injury

Combination immunotherapy in Japanese patients with advanced renal cell carcinoma: bridging gaps between clinical trials, real-world evidence, and the potential value of adverse events-a narrative review. (PubMed, Transl Cancer Res) - "Nivolumab plus ipilimumab (NIVO + IPI) and various ICI + TKI regimens (avelumab + axitinib, pembrolizumab + axitinib, nivolumab + cabozantinib, pembrolizumab + lenvatinib) have shown superior efficacy to sunitinib in pivotal trials...TRAEs show promise as prognostic markers in NIVO + IPI but require further validation in ICI + TKI. Prospective multicenter registries with standardized adverse event reporting, coupled with translational studies, are needed to refine regimen selection and personalized therapy."

Adverse events • HEOR • IO biomarker • Journal • Real-world evidence • Review • Genito-urinary Cancer • Kidney Cancer • Non Clear Cell Renal Cell Carcinoma • Oncology • Renal Cell Carcinoma • Solid Tumor

Lost in translation: Do preclinical studies predict clinical failure in GBM? (SNO 2025) - "For the trials evaluated, no preclinical brain:plasma (B/P) data were reported for enzastaurin, cilengitide, nimotuzumab, Depatux-M, or bevacizumab, although IgG typically has a B/P ≈1%...The best response for each drug compared to relevant control (relative increase in median survival) was 22% (nimotuzumab), 31% (marizomib), 36% (sunitinib CD) / 5% (sunitinib PD), 63% (bevacizumab/temozolomide), 140% (imatinib), 157% (Depatux-M), 220% (veliparib/temozolomide), 300% (cediranib); median survival was not reached for cilengitide...The stunning lack of clinical progress in GBM is deeply discouraging, but is consistent with underwhelming preclinical testing and the contextual interpretation of those results. Acknowledging multifaceted reasons for failed clinical trials, a more rigorous and critical approach should be used in preclinical studies, coupled with follow-up surgical window of opportunity studies, to identify and promote only the most promising therapies into..."

Preclinical • Brain Cancer • CNS Disorders • Glioblastoma • Solid Tumor

Lost in translation: Do preclinical studies predict clinical failure in GBM? (SNO 2025) - "For the trials evaluated, no preclinical brain:plasma (B/P) data were reported for enzastaurin, cilengitide, nimotuzumab, Depatux-M, or bevacizumab, although IgG typically has a B/P ≈1%...The best response for each drug compared to relevant control (relative increase in median survival) was 22% (nimotuzumab), 31% (marizomib), 36% (sunitinib CD) / 5% (sunitinib PD), 63% (bevacizumab/temozolomide), 140% (imatinib), 157% (Depatux-M), 220% (veliparib/temozolomide), 300% (cediranib); median survival was not reached for cilengitide...The stunning lack of clinical progress in GBM is deeply discouraging, but is consistent with underwhelming preclinical testing and the contextual interpretation of those results. Acknowledging multifaceted reasons for failed clinical trials, a more rigorous and critical approach should be used in preclinical studies, coupled with follow-up surgical window of opportunity studies, to identify and promote only the most promising therapies into..."

Preclinical • Brain Cancer • CNS Disorders • Glioblastoma • Solid Tumor

Lost in translation: Do preclinical studies predict clinical failure in GBM? (WFNOS 2025) - "For the trials evaluated, no preclinical brain:plasma (B/P) data were reported for enzastaurin, cilengitide, nimotuzumab, Depatux-M, or bevacizumab, although IgG typically has a B/P ≈1%...The best response for each drug compared to relevant control (relative increase in median survival) was 22% (nimotuzumab), 31% (marizomib), 36% (sunitinib CD) / 5% (sunitinib PD), 63% (bevacizumab/temozolomide), 140% (imatinib), 157% (Depatux-M), 220% (veliparib/temozolomide), 300% (cediranib); median survival was not reached for cilengitide...The stunning lack of clinical progress in GBM is deeply discouraging, but is consistent with underwhelming preclinical testing and the contextual interpretation of those results. Acknowledging multifaceted reasons for failed clinical trials, a more rigorous and critical approach should be used in preclinical studies, coupled with follow-up surgical window of opportunity studies, to identify and promote only the most promising therapies into..."

Preclinical • Brain Cancer • CNS Disorders • Glioblastoma • Oncology • Solid Tumor

Lost in translation: Do preclinical studies predict clinical failure in GBM? (WFNOS 2025) - "For the trials evaluated, no preclinical brain:plasma (B/P) data were reported for enzastaurin, cilengitide, nimotuzumab, Depatux-M, or bevacizumab, although IgG typically has a B/P ≈1%...The best response for each drug compared to relevant control (relative increase in median survival) was 22% (nimotuzumab), 31% (marizomib), 36% (sunitinib CD) / 5% (sunitinib PD), 63% (bevacizumab/temozolomide), 140% (imatinib), 157% (Depatux-M), 220% (veliparib/temozolomide), 300% (cediranib); median survival was not reached for cilengitide...The stunning lack of clinical progress in GBM is deeply discouraging, but is consistent with underwhelming preclinical testing and the contextual interpretation of those results. Acknowledging multifaceted reasons for failed clinical trials, a more rigorous and critical approach should be used in preclinical studies, coupled with follow-up surgical window of opportunity studies, to identify and promote only the most promising therapies into..."

Preclinical • Brain Cancer • CNS Disorders • Glioblastoma • Glioma • Oncology • Solid Tumor

Electroacupuncture Prevents Against AD-Like Phenotypes in APP/PS1 Mice: Investigation of the Mechanisms From Cerebral Microangiopathy. (PubMed, CNS Neurosci Ther) - "Our data demonstrates that EA ameliorates AD-like phenotypes, potentially through preventing microangiopathy."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • CD31 • CLDN5 • FUS • OCLN • PDGFRB • PECAM1 • SLC2A1 • TJP1

Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial. (PubMed, Cancer) - "After two additional years of follow-up, ripretinib showed a trend toward clinically meaningful OS benefit versus sunitinib in the Ex11 ITT population. Second-line ripretinib does not appear to affect third-line treatment efficacy."

Clinical • Journal • P2 data • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Oncology • Sarcoma

Restricted Mean Survival Time–Based Comparative Effectiveness of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma (SUO 2025) - " Compared with sunitinib, OS dRMST was 4.15 months (95% CI: 1.86–6.45, p<0.001) for Nivolumab + Cabozantinib (NIVO–CABO), 3.53 (1.43–5.62, p=0.001) for Lenvatinib + Pembrolizumab (LEN–PEM), 2.75 (0.97–4.53, p=0.002) for Nivolumab + Ipilimumab (NIVO–IPI), and 2.68 (0.77–4.58, p=0.005) for Pembrolizumab + Axitinib (PEM–AXI)... RMST-based analysis enables nuanced comparison of ICI regimens in mRCC, highlighting modest OS benefit, greater PFS separation, cost differences, and distinct toxicity burdens. Nivolumab + Cabozantinib demonstrated the greatest OS benefit, while Lenvatinib + Pembrolizumab achieved the highest PFS gain. These findings underscore the importance of integrating multiple treatment attributes—beyond hazard ratios—into personalized treatment decision-making."

Checkpoint inhibition • Clinical • HEOR • Metastases • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

REVISITING CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA: REAL-WORLD EVIDENCE OF SURVIVAL BENEFIT IN THE ERA OF MODERN IMMUNOTHERAPY AND TARGETED THERAPY (SUO 2025) - "Evidence from the Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) and the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients with Metastatic Kidney Cancer (SURTIME) trials have questioned the role of CRN...Using relevant ICD-10 codes and CPT codes, cohorts of patients with mRCC receiving any kind of systemic therapy (n= 1776), Axitinib and Pembrolizumab (n= 470), Cabozantinib and Nivolumab (n=774), Lenvatinib and Pembrolizumab (n = 246), and Ipilimumab and Nivolumab (n= 958), were identified... Although the use of CRN in patients with mRCC has steadily declined since 2012, our large-scale real-world analysis demonstrates that CRN is associated with a significant survival benefit in most patients with mRCC receiving contemporary systemic combination therapy. These findings highlight the continued relevance of CRN in well selected patients and underscore the need to revisit CRN in the immunotherapy era with prospective..."

Clinical • HEOR • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy. (PubMed, Oncol Ther) - P3 | "Removing the effect of subsequent therapy strengthened the relative OS benefit of CaboNivo versus SUN in CM9ER. Consistent with clinical practice, these results further support first-line CaboNivo as a standard of care for aRCC. Graphical abstract available for this article."

Journal • P3 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Network Meta-Analysis for an Efficacy Assessment of Avelumab Axitinib in the First-Line Treatment of International Metastatic RCC Database Consortium (IMDC) Favorable Risk Patients With Advanced Renal Cell Carcinoma (ARCC) (ISPOR-EU 2025) - "Relevant treatment comparators with reported results in this subgroup included sunitinib, nivolumab + ipilimumab (nivo + ipi), pembrolizumab + lenvatinib (pem + len) and nivolumab + cabozantinib (nivo + cabo). Subgroup data from four randomized controlled trials (RCTs) were suitable for indirect treatment comparisons (JAVELIN Renal 101 [ave + axi, n=188], CheckMate 214 [nivo + ipi, n=249], CheckMate 9ER [nivo + cabo, n=146] and CLEAR [pem + len, n=234])... These findings support the role of ave + axi as a 1L treatment option for IMDC favorable risk aRCC patients. Results have shown that ave + axi performed numerically better than 3 of the 4 comparator treatments for OS and better than 2 of the 4 comparators for PFS, with numerically similar results to 1 comparator in both OS and PFS."

Metastases • Retrospective data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

The structural requirements of 3,5-substituted oxindoles that determine selective AMPK or GSK3β inhibition. (PubMed, RSC Med Chem) - "We have previously reported a structure-activity study of substituted oxindoles based on the multi-kinase inhibitor sunitinib to determine the structural requirements for AMPK inhibition and found that a 5-(2-cyanoethyl)-substituted oxindole displayed selectivity for AMPK over VEGFR-2...Here, we report a further series of 3,5-substituted oxindoles that demonstrate that 5-cyano-oxindoles can inhibit both GSK3β and AMPK, but the 5-(2-cyanoethyl)-substitution and the orientation of the 3-substituent of the oxindole are critical determinants for AMPK inhibition and selectivity. These findings could have critical importance in evaluating metabolic targeting in cancer as GSK3β promotes anabolic pathways and suppresses AMPK activity."

Journal • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • ACACB • AMPK • KDR

Overexpression of CSRP1 Suppresses Cell Viability and Enhances the Anti-Cancer Effects of Anti-PD-L1 Therapy in Renal Cell Carcinoma. (PubMed, Front Biosci (Landmark Ed)) - "CSRP1 may play a role in regulating cell viability, migration, drug resistance, and possibly innate immunity in RCC. These findings suggest that CSRP1 could increase the efficacy of targeted drugs and immunotherapy in combination treatment strategies for RCC."

IO biomarker • Journal • Acute Myelogenous Leukemia • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

Potent and selective G protein-coupled receptor kinase 5 inhibitors: Design, synthesis, evaluation, and X-ray structural studies. (PubMed, Eur J Med Chem) - "Utilizing pyrroloindolinone as the main scaffold, which is embedded in the FDA-approved, orally bioavailable anti-cancer drug, sunitinib, we used structure-based design to generate a series of noncovalent, and drug-like GRK5 inhibitors...Three high-resolution X-ray crystal structures of GRK5-inhibitor complexes were determined to obtain insights into the ligand-binding site interactions. The current structure-activity studies and X-ray structural insights will further enable development of GRK5 inhibitor-based new treatments against cancer and heart diseases."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Oncology

Spontaneous hepatic rupture: A catastrophic complication in a patient with primary splenic angiosarcoma and hepatic metastasis: case report and literature review. (PubMed, Front Oncol) - "The patient received postoperative chemotherapy (liposomal paclitaxel) and subsequent targeted therapy (sunitinib). This case demonstrates the potential inefficacy of sunitinib against PSA-derived hepatic metastases and emphasizes the critical importance of early diagnosis and intervention before splenic rupture occurs. The potential for combination therapies, including immunotherapy, to represent future investigative avenues is a promising area for future research."

Journal • Angiosarcoma • Hepatocellular Cancer • Oncology • Pain • Sarcoma • Solid Tumor

Case Report of Rare Metastasis of Renal Cell Carcinoma to the Bladder: A New Hypothesis and Literature Review. (PubMed, Arch Esp Urol) - "Solitary resectable intravesical metastatic RCC is a good prognostic factor. Late-onset systemic metastasis may be observed and should be considered during follow-up. PET-CT scanning should be performed if necessary, and the patient can be treated with sunitinib."

Journal • Review • Bladder Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Pain • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer

Association of G-coupled protein receptor 65 (GPR65), a novel therapeutic target, with immune cell subsets in metastatic renal cell carcinoma (mRCC) (ESMO-IO 2025) - P1/2 | "Non-negative Matrix Factorization clustering in IMmotion151 revealed enrichment of T-effector/proliferative programs in GPR65high (p<0.00001); this same cluster previously has shown improved ORR and PFS with atezolizumab + bevacizumab versus sunitinib in IMmotion151. In RCC explants, PTT-3213 reduced anti-inflammatory cytokines (e.g., IL-10) and increased chemoattractant cytokines (e.g., CCL3), indicating pro-inflammatory, anti-tumor TME with GPR65 inhibition.Conclusions GPR65 expression marks a highly immune infiltrated yet functionally restrained TME, correlating with PD-L1 expression and T-effector signatures. These findings position GPR65 as a putative therapeutic target and support combination strategies in mRCC, aligning with an ongoing phase 1 trial of a GPR65 inhibitor in solid tumors (NCT06634849).Legal entity responsible for the study The authors."

Immune cell • IO biomarker • Metastases • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CCL3 • CD4 • CD8 • IL10 • PD-L1

Vanishing clear cell carcinoma of the kidney presenting with skin metastases - a case report. (PubMed, Ecancermedicalscience) - "Despite commencing palliative Sunitinib therapy based on intermediate risk criteria, the patient died from lung metastases after 6 months of systemic medication. Here is a more succinct version. This case report emphasises the need to investigate renal primaries in unknown-origin metastases and the importance of a thorough diagnostic approach for RCC."

Journal • Acute Kidney Injury • Clear Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Nephrology • Oncology • Pain • Renal Cell Carcinoma • Renal Disease • Solid Tumor